Celiac Therapeutics - A Pipeline Analysis report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for celiac therapeutics including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentation such as therapy, route of administration, and target.

Overview of the drug development pipeline for celiac therapeutics

Celiac disease is also known as celiac sprue, non-tropical sprue, and gluten-sensitive enteropathy. It is one of the serious autoimmune diseases that can occur genetically predisposed people. The common symptoms of celiac disease are damaged inner walls of the small intestine. When people with celiac diseases consume gluten in their diet, an immune response gets triggered, which affects the small intestine. This condition causes damage to the villi, which are small finger-like projections lining the small intestine making it difficult for the body to absorb nutrients. Celiac disease can occur in individuals of any age group at any time of their life and later develop into a critical health issue if left untreated. A few common symptoms of celiac disease are diarrhea, constipation, and bloating. Monotherapy is emerging as the most efficient approach for the treatment of celiac disease in the past few years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for celiac therapeutics. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Drug development pipeline report for celiac therapeutics: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of celiac disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Amgen
• BioLineRx
• Bioniz

Therapeutic assessment of the drug development pipeline for celiac therapeutics by route of administration

• Oral
• Intravenous
• Subcutaneous
• Unknown

The oral route of administration (ROA) involves the placement of the drug directly into the mouth cavity and in the intravenous technique, the molecules are injected into the vein, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for celiac therapeutics by therapy

• Monotherapy
• Unknown

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for celiac therapeutics are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages for celiac therapeutics?
• What are the companies that are currently involved in the development of drug molecules for celiac therapeutics?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.